Trial
NCT01416181
A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
—
Condition
Secondary Progressive Multiple Sclerosis
Intervention
natalizumab
Why stopped
The ASCEND Study did not achieve statistical significance on the primary or secondary endpoints.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-09-11